Market Movers

West Pharmaceutical Services, Inc.’s Stock Price Plummets to $199.11, Recording a Steep -38.22% Decline

By February 14, 2025 No Comments

West Pharmaceutical Services, Inc. (WST)

199.11 USD -123.17 (-38.22%) Volume: 5.12M

West Pharmaceutical Services, Inc.’s stock price currently sits at 199.11 USD, experiencing a substantial decrease of -38.22% in the latest trading session with a significant trading volume of 5.12M. The stock’s year-to-date performance also reflects a downward trend, with a percentage change of -37.44%.


Latest developments on West Pharmaceutical Services, Inc.

West Pharmaceutical Services Inc. has been in the spotlight recently due to its fourth-quarter and full-year 2024 results announcement. Despite beating revenue expectations, the stock took a hit, dropping 33% and leading the S&P 500 decliners list as guidance missed estimates by a wide margin. The company’s Q4 profit decreased but still managed to beat estimates, causing fluctuations in stock prices. Earnings call transcripts revealed that West Pharmaceutical exceeded EPS forecasts, yet the stock continued to drop. The bleak forecast for 2025 results contributed to the stock sinking further, hitting a 52-week low. Despite challenges ahead, the company’s strong Q4 performance and strategic positioning have garnered a buy rating from analysts. Investors have been actively buying and selling shares of West Pharmaceutical Services Inc., with various financial institutions adjusting their positions based on the latest earnings reports and forecasts.


West Pharmaceutical Services, Inc. on Smartkarma

Analysts at Baptista Research on Smartkarma have published a bullish research report on West Pharmaceutical Services Inc. The report titled “West Pharmaceutical Services: Expanding Capacity in High-Value Product Lines & Unlocking Commercial Manufacturing Potential! – Major Drivers” discusses the company’s third-quarter earnings, highlighting steady performance amidst market challenges. The analysts commend the company’s effective execution of strategic initiatives while addressing customer destocking and shifts in demand. Baptista Research aims to assess various factors influencing the company’s stock price in the near future and conduct an independent valuation using a Discounted Cash Flow (DCF) methodology.


A look at West Pharmaceutical Services, Inc. Smart Scores

FactorScoreMagnitude
Value2
Dividend2
Growth3
Resilience3
Momentum4
OVERALL SMART SCORE2.8

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

West Pharmaceutical Services Inc has a moderate outlook when it comes to value and dividend, scoring a 2 out of 5 in both categories. However, the company shows promise in terms of growth, resilience, and momentum, scoring a 3, 3, and 4 respectively. This indicates that while the company may not be offering the highest value or dividend at the moment, it is showing positive signs of growth and resilience in the long term.

West Pharmaceutical Services, Inc. is a company that focuses on providing value-added services in the healthcare industry. With a strong emphasis on designing and manufacturing packaging components, researching drug delivery systems, and offering contract laboratory services, the company plays a crucial role in bringing new drug therapies and healthcare products to global markets. Despite some average scores in certain areas, the company’s overall outlook appears positive, especially in terms of growth and momentum.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars